Epigenetic regulation affects N-myc downstream-regulated gene 1 expression indirectly in pancreatic cancer cells

Pancreas

Volumn 39, Issue 5, 2010, Pages 675-679

  Angst, Eliane ^a,b   Dawson, David W ^c   Nguyen, Anne ^c   Park, Jenny ^a,b   Go, Vay L W ^b   Reber, Howard A ^a,b   Hines, Oscar Joe ^a,b   Eibl, Guido ^a,b  

^a Hirshberg Laboratories for Pancreatic Cancer Research   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

deacetylation; epigenetic modification; methylation; N myc downstreamYregulated gene 1; pancreatic cancer

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NDRG 1; TRICHOSTATIN A; UNCLASSIFIED DRUG; AZACITIDINE; CELL CYCLE PROTEIN; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; N-MYC DOWNSTREAM-REGULATED GENE 1 PROTEIN; SIGNAL PEPTIDE;

ARTICLE; CANCER CELL; CPG ISLAND; DNA METHYLATION; DOWNSTREAM PROCESSING; EPIGENETICS; GENE EXPRESSION; GENE SEQUENCE; GENE TARGETING; GENETIC REGULATION; HUMAN; HUMAN CELL; N MYC DOWNSTREAM REGULATED GENE 1; NUCLEOTIDE SEQUENCE; ONCOGENE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; PANCREAS TUMOR; PROMOTER REGION; TUMOR CELL CULTURE;

AZACITIDINE; CELL CYCLE PROTEINS; CPG ISLANDS; DNA METHYLATION; DNA MODIFICATION METHYLASES; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; TUMOR CELLS, CULTURED;

EID: 77954140840     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181c8b476     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Kazanjian KK, Hines OJ, Duffy JP, et al. Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss. Arch Surg. 2008;143:1166-1171.
3. Storniolo AM, Enas NH, Brown CA, et al. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer. 1999;85:1261-1268.
4. van Riel JM, van Groeningen CJ, Pinedo HM, et al. Current chemotherapeutic possibilities in pancreaticobiliary cancer. Ann Oncol. 1999;10(suppl 4):157-161.
5. van Belzen N, Dinjens WN, Eussen BH, et al. Expression of differentiation-related genes in colorectal cancer: possible implications for prognosis. Histol Histopathol. 1998;13:1233-1242.
6. Angst E, Sibold S, Tiffon C, et al. Cellular differentiation determines the expression of the hypoxia-inducible protein NDRG1 in pancreatic cancer. Br J Cancer. 2006;95:307-313.
7. Maruyama Y, Ono M, Kawahara A, et al. Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/ NDRG1/Drg-1 through modulation of angiogenesis. Cancer Res. 2006;66:6233-6242.
8. Bandyopadhyay S, Pai SK, Gross SC, et al. The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res. 2003;63:1731-1736.
9. Hamacher R, Schmid RM, Saur D, et al. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer. 2008;7:64.
10. Park JY, Helm JF, Zheng W, et al. Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancer. Pancreas. 2008;36:e32-e39.
11. Bandyopadhyay S, Pai SK, Hirota S, et al. Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression. Oncogene. 2004;23:5675-5681. (Pubitemid 39093045)
12. Guan RJ, Ford HL, Fu Y, et al. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res. 2000;60:749-755.
13. Shimono A, Okuda T, Kondoh H. N-myc-dependent repression of ndr1, a gene identified by direct subtraction of whole mouse embryo cDNAs between wild type and N-myc mutant. Mech Dev. 1999;83:39-52.
14. Eibl G, Takata Y, Boros LG, et al. Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. Cancer Res. 2005;65:982-990.
15. Hasan S, Satake M, Dawson DW, et al. Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers. Pancreas. 2008;37:121-127.
16. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997;25:2532-2534.
17. Cangul H. Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers. BMC Genet. 2004;5:27.
18. Zhang P, Tchou-Wong KM, Costa M. Egr-1 mediates hypoxia-inducible transcription of the NDRG1 gene through an overlapping Egr-1/Sp1 binding site in the promoter. Cancer Res. 2007;67:9125-9133.
19. Buchler P, Reber HA, Buchler M, et al. Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas. 2003;26:56-64.
20. Zhang AH, Rao JN, Zou T, et al. p53-dependent NDRG1 expression induces inhibition of intestinal epithelial cell proliferation but not apoptosis after polyamine depletion. Am J Physiol Cell Physiol. 2007;293:C379-C389.
21. Stein S, Thomas EK, Herzog B, et al. NDRG1 is necessary for p53-dependent apoptosis. J Biol Chem. 2004;279:48930-48940.
22. Sipos B, Moser S, Kalthoff H, et al. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch. 2003;442:444-452.
23. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28:622-629.
24. Li J, Kretzner L. The growth-inhibitory Ndrg1 gene is a Myc negative target in human neuroblastomas and other cell types with overexpressed N- or c-myc. Mol Cell Biochem. 2003;250:91-105.
25. Zhang J, Chen S, Zhang W, et al. Human differentiation-related gene NDRG1 is a Myc downstream-regulated gene that is repressed by Myc on the core promoter region. Gene. 2008;417:5-12.
26. Fukushige S, Waldman FM, Kimura M, et al. Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma. Genes Chromosomes Cancer. 1997;19:161-169.
27. Kowalski J, Morsberger LA, Blackford A, et al. Chromosomal abnormalities of adenocarcinoma of the pancreas: identifying early and late changes. Cancer Genet Cytogenet. 2007;178:26-35.
28. Zojer N, Fiegl M, Mullauer L, et al. Chromosomal imbalances in primary and metastatic pancreatic carcinoma as detected by interphase cytogenetics: basic findings and clinical aspects. Br J Cancer. 1998; 77:1337-1342.
29. Heidenblad M, Schoenmakers EF, Jonson T, et al. Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines. Cancer Res. 2004;64:3052-3059.
30. Adsay NV, Dergham ST, Koppitch FC, et al. Utility of fluorescence in situ hybridization in pancreatic ductal adenocarcinoma. Pancreas. 1999;18:111-116.
31. Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. New York, NY: Garland Science; 2002.
32. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26:5541-5552.
33. Banz VM, Medova M, Keogh A, et al. Hsp90 transcriptionally and post-translationally regulates the expression of NDRG1 and maintains the stability of its modifying kinase GSK3beta. Biochim Biophys Acta. 2009;1793:1597-1603.